President Trump has taken some action to help companies like EpiPen maker Mylan get their drug deal approved.
Trump’s move comes as the company struggles to get its deal for EpiPens approved and has been stuck in a lengthy process to secure an extension to the approval process.
The company is now awaiting approval from the Food and Drug Administration (FDA) and the Department of Justice (DOJ) to move forward with its plans to sell more than 60 million of its EpiPad pen and epinephrine injector devices.
Trump has granted two extensions of time to expedite the approval of the EpiProne injectors, according to the Wall Street Journal.
Trump has also granted three extensions of deadlines for approval of Mylan’s generic versions of the devices, including for the Epinelo, Mylano and Mylanpac injectors.
According to the Journal, Mylanta is the only company that has not been granted an extension for its Epinero injectors to move ahead with its approval process and could face delays of up to a year.
The company has not yet filed a request for an extension of the FDA’s approval of its generic versions, but Trump has extended the time by two years.
“If I can give the agency another two years to make the decision, I think it will be easier,” Trump said in a press conference on March 22.
EpiPen has been under pressure for years because of the high cost of EpiCoat.
With the FDA still waiting for Mylan to get Epinalo injectors approved, the company is considering selling off its remaining stock in the company, according the Journal.
It would be the largest such deal in history.
In a statement, Mylon said it had not received a request from the administration for extensions of the approvals for its two Epinrojectors to go forward with their applications.
But, Mylo has said it will sell off some of its stake in the pharmaceutical company.
Earlier this month, Myln said it would sell off all of its stock by June 15.
Follow Joe on Twitter: @joe_fertittaJoe